LEVOFLOXACIN LACTATE

Details

Stereochemistry	RACEMIC
Molecular Formula	C18H20FN3O4.C3H6O3
Molecular Weight	451.4454
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 2
E/Z Centers	0
Charge	0
Stereo Comments	C3 H6 O3

SHOW SMILES / InChI

Structure Search

SMILES

CC(O)C(O)=O.C[C@H]1COC2=C(N3CCN(C)CC3)C(F)=CC4=C2N1C=C(C(O)=O)C4=O

InChI

InChIKey=ONDRRTIAGBDDKP-PPHPATTJSA-N

InChI=1S/C18H20FN3O4.C3H6O3/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21;1-2(4)3(5)6/h7-8,10H,3-6,9H2,1-2H3,(H,24,25);2,4H,1H3,(H,5,6)/t10-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C3H6O3
Molecular Weight	90.0779
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	C18H20FN3O4
Molecular Weight	361.3675
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf

Levofloxacin is the L-isomer of the racemate, ofloxacin, a quinolone antimicrobial agent. Levofloxacin is used for oral and intravenous administration. Levofloxacin is sold under brand name levaquin and is used to treat infections in adults (≥18 years of age) caused by designated, susceptible bacteria such as, pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. In addition this drug is used to treat plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Levofloxacin, like other fluoroquinolones, inhibits the bacterial DNA gyrase, halting DNA replication. This results in strand breakage on a bacterial chromosome, supercoiling, and resealing. In addition, levofloxacin inhibits a bacterial type II topoisomerase.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Topoisomerase IV 62 Target ID: CHEMBL2363033 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26525786	Inhibitor 8504
DNA gyrase 26 Target ID: CHEMBL2311225 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26459538	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Pneumonia 91 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf	Curative	Approved 8583	LEVAQUIN Approved Use LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date 1996
Complicated Skin and Skin Structure Infections 6 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf	Curative	Approved 8583	LEVAQUIN Approved Use LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date 1996
Chronic bacterial prostatitis 6 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf	Curative	Approved 8583	LEVAQUIN Approved Use LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date 1996
Plague 14 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf	Curative	Approved 8583	LEVAQUIN Approved Use LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date 1996
Chronic bronchitis 52 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf	Curative	Approved 8583	LEVAQUIN Approved Use LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date 1996
Urinary tract infections 207 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf	Curative	Approved 8583	LEVAQUIN Approved Use LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date 1996

C_max

Value	Dose	Analyte	Population
2.04 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
8.85 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
11.8 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7.8 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
6.3 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7.9 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
19.88 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
111 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
118 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
59 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
55.3 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
49.6 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
5.97 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7.9 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
8.9 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
8.4 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
6.6 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7.6 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf	unhealthy, mean 50 years Health Status: unhealthy Age Group: mean 50 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf	Disc. AE: Gastrointestinal disorder, Nausea... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (1.4%) Nausea (0.6%) Vomiting (0.4%) Dizziness (0.3%) Headache (0.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf
500 mg 1 times / day steady, oral Recommended Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf	unhealthy, mean 50 years Health Status: unhealthy Age Group: mean 50 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf	Disc. AE: Gastrointestinal disorder, Nausea... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (1.4%) Nausea (0.6%) Vomiting (0.4%) Dizziness (0.3%) Headache (0.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf
750 mg 1 times / day steady, oral Recommended Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf	unhealthy, mean 50 years Health Status: unhealthy Age Group: mean 50 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf	Disc. AE: Gastrointestinal disorder, Nausea... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (1.2%) Nausea (0.6%) Vomiting (0.5%) Dizziness (0.3%) Headache (0.3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 substrate 1946	inhibitor 2438 substrate 1193	inhibitor 2507 substrate 1388	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2B6 926 CYP2C8 1057 CYP2C19 2057 OCTN2 71	CYP1A2 1197 CYP2C19 1119 UGT1A1 479 UGT1A3 470 UGT1A4 399 UGT1A6 343 UGT1A7 249 UGT1A8 323 UGT1A10 331 OATP1A2 67 OATP2B1 122 OATP1B1 503 OATP1B3 435 P-gp 2052 BCRP 697

Drug as perpetrator

Target	Modality	Activity	Metabolite
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	inconclusive	levofloxacin-N-oxide 6
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/19026171/ Page: -	no
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP2B6 1160	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP2C8 1117	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP3A4 2633	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	weak	levofloxacin-N-oxide 6
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/19026171/ Page: -	yes [IC50 210 uM]
OCTN2 71	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/16928358/ Page: -	yes [IC50 6800 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	yes	levofloxacin-N-oxide 6
CYP2D6 2546	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	yes	levofloxacin-N-oxide 6

Drug as victim

Target	Modality	Activity	Metabolite
CYP1A2 1197	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP2C19 1119	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP2C9 1193	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP2D6 1388	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
OATP1B1 503	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/17274666/ Page: -	no
OATP1B3 435	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/17274666/ Page: -	no
OATP2B1 122	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/17274666/ Page: -	no
UGT1A10 331	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	no
UGT1A4 399	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	no
UGT1A6 343	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	no
UGT1A8 323	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	no
OATP1A2 67	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/17274666/ Page: -	yes [Km 136 uM]
BCRP 697	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/17978494/ Page: -	yes
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/17978494/ Page: -	yes
UGT1A1 479	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	yes
UGT1A3 470	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	yes
UGT1A7 249	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubmed.ncbi.nlm.nih.gov/16474415/ Page: -

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B1-01436	http://www.3bsc.com/index/pro_info.php?id=21648
3B Scientific (Wuhan) Corp	3B2-6360	http://www.3bsc.com/index/pro_info.php?id=122847
AA Blocks	AA0003AY	http://www.aablocks.com/goods/Goods/detail?id=AA0003AY
Aaron Chemicals	AR00042Q	http://www.aaronchem.com/100986-85-4
abcr GmbH	AB250203	http://www.abcr.com/shop/en/AB250203
Achemtek	0104-011027	http://www.achemtek.com/138199-71-0
Achemtek	0104-018860	http://www.achemtek.com/100986-85-4
Acorn PharmaTech	ACN-038325	http://www.acornpharmatech.com/
AEchem Scientific Corp., USA	AE020182	http://www.aechemsc.com/info_products/AE020182.php
Alsachim	853	http://www.alsachim.com/product-C2615-glo.bal-view.html
Ambinter	Amb20669810	http://www.ambinter.com/reference/20669810
Ambinter	Amb2444040	http://www.ambinter.com/reference/2444040
ApexBio Technology	A5511	http://www.apexbt.com/ofloxacin.html
ApexBio Technology	B1959	http://www.apexbt.com/levofloxacin.html
Aurora Fine Chemicals LLC	A17.890.330	http://online.aurorafinechemicals.com/info?ID=A17.890.330
BioSynth	Q-201295	https://www.biosynth.com/en/products/life-science/culture-media-additives/products/Q-201295.html
BLD Pharm	BD0022	http://www.bldpharm.com/products/100986-85-4.html
Chem Scene	CS-2218	http://www.chemscene.com/100986-85-4.html
Chemenu	CM110290	http://www.chemenu.com/products/CM110290
ChemMol	30101095	http://www.chemmol.com/chemmol/30101095.html
ChemMol	49401467	http://www.chemmol.com/chemmol/49401467.html
Chemspace	CSSB00016993440	https://chem-space.com/CSSB00016993440
Clearsynth	CS-O-01741	http://www.clearsynth.com/en/CSO01741.html
CSNpharm	CSN10001	https://www.csnpharm.com/products/levofloxacin.html
DC Chemicals	DCAPI1002	http://www.dcchemicals.com//product_show-Levofloxacin_Levaquin_.html
eNovation Chemicals	D674497	https://www.enovationchem.com/ProductDetails.asp?ProductID=D674497
eNovation Chemicals	Y1040229	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y1040229
Excenen	EX-A1488	http://www.excenen.com/searchresultlist.php?id=100986-85-4
Hairui	HR127302	http://www.hairuichem.com/en/product/100986-85-4.html
iChemical	EBD8264	http://www.ichemical.com/products/100986-85-4.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network	LN00235793	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00235793
LGC Standards	DRE-C14629730	https://www.lgcstandards.com/US/en/p/DRE-C14629730
LGC Standards	LGCFOR0846.00	https://www.lgcstandards.com/US/en/p/LGCFOR0846.00
LGC Standards	MM0846.00	https://www.lgcstandards.com/US/en/p/MM0846.00
mcule	MCULE-2011834955	https://mcule.com/MCULE-2011834955/
MedChem Express	HY-B0330	https://www.medchemexpress.com/Levofloxacin.html
MuseChem	I000113	https://www.musechem.com/product/I000113.html
OChem	3793	http://www.ocheminc.com/index.php?act=psearch&pid=986L854
Otava	12488923	https://search.otavachemicals.com/#!/search?query=12488923&type=code&base=dbb
Sigma-Aldrich	28266_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/28266?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	40922_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/40922?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	L-038_CERILLIAN	https://www.sigmaaldrich.com/catalog/product/cerillian/l038?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S061060	http://www.sinfoobiotech.com/product/1064463
Smolecule	S532946	http://www.smolecule.com/products/s532946
TCI (Tokyo Chemical Industry)	L0193	http://www.tcichemicals.com/eshop/en/us/commodity/L0193/index.html
THE BioTek	bt-273347	https://www.thebiotek.com/product/inhibitors/bt-273347
VladaChem	VL261985-25G	https://www.vladachem.com/product.php?products=100986-85-4
Yuhao Chemical	LT1250	http://www.chemyuhao.com/100986-85-4.html

PubMed

Title	Date	PubMed
A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae.	2001-08-15	11462189
Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States.	2001-07-13	11448565
Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.	2001-07-13	11448564
Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp.	2001-07-13	11448563
In vitro activity of ABT-773 versus macrolides and quinolones against resistant respiratory tract pathogens.	2001-07-13	11448561
Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp.	2001-07	11463526
Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams.	2001-07	11463525
New directions in antiinfective therapy for community-acquired pneumonia in the emergency department.	2001-07	11446525
A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.	2001-07	11446524
Intravenous-to-oral transition therapy in community-acquired pneumonia: the INOVA Health System experience.	2001-07	11446523
The use of fluoroquinolones as antiinfective transition-therapy agents in community-acquired pneumonia.	2001-07	11446520
Levofloxacin and warfarin interaction.	2001-07	11444586
The in vivo activity of olamufloxacin (HSR-903) in systemic and urinary tract infections in mice.	2001-07	11418525
Activity of levofloxacin and ciprofloxacin against urinary pathogens.	2001-07	11418511
Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa?	2001-06-16	11399859
Comparison of in-vitro activities of SCH27899 and other antibiotics against Mycoplasma pneumoniae.	2001-06	11455504
Complicated urinary tract infections in patients with voiding dysfunction.	2001-06	11442992
Effect of levofloxacin on theophylline clearance during theophylline and clarithromycin combination therapy.	2001-06	11408986
Levofloxacin failure in a patient with pneumococcal pneumonia.	2001-06	11408985
Antimicrobial resistance and serotype distribution of Streptococcus pneumoniae isolates from Crete, Greece.	2001-06	11397616
Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.	2001-06	11397615
Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.	2001-06	11389122
Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.	2001-06	11389113
Abiotrophia bacteremia in a patient with neutropenic fever and antimicrobial susceptibility testing of Abiotrophia isolates.	2001-05-15	11317266
Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.	2001-05	11388112
Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein.	2001-05	11370709
Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.	2001-05	11337224
Tissue penetration of a single dose of levofloxacin intravenously for antibiotic prophylaxis in lung surgery.	2001-05	11328803
Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens.	2001-05	11328784
Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones.	2001-05	11328779
Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model.	2001-05	11328772
[Levofloxacin adverse effects, data from clinical trials and pharmacovigilance].	2001-04-27	11322015
[Use of levofloxacine in primary care for outbreaks in COPD].	2001-04-15	11334579
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.	2001-04	11404068
Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).	2001-04	11404067
In vitro activity of gemifloxacin (SB-265805) compared to eleven other antimicrobial agents against streptococcal isolates, excluding Streptococcus pneumoniae.	2001-04	11399019
[Comparison of in vitro antimicrobial activities of ofloxacin, levofloxacin, ciprofloxacin, and sparfloxacin against various mycobacteria].	2001-04	11398326
Enantioseparation of ofloxacin in urine by capillary electrokinetic chromatography using charged cyclodextrins as chiral selectors and assessment of enantioconversion.	2001-04	11379965
In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones.	2001-04	11322420
Comparison of antimycobacterial activity of grepafloxacin against Mycobacterium avium with that of levofloxacin: accumulation of grepafloxacin in human macrophages.	2001-03	11406752
Activity of oral agents against pediatric isolates of Streptococcus pneumoniae.	2001-03	11337189
Antidepressant, anxiogenic, and antinociceptive properties of levofloxacin in rats and mice.	2001-03	11325396
Treatment of tularemia with levofloxacin.	2001-03	11318818
Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials.	2001-03	11318077
Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration.	2001-02	11396281
Quinolones alter defense reactions mediated by macrophages.	2001-02	11360919
Effects of common topical otic preparations on the morphology of isolated cochlear outer hair cells.	2001-01	11349764
In vitro activity of levofloxacin against coagulase-positive and -negative staphylococci.	2001	11447768
A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.	2001	11347723
Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.	2001	11327197

Patents

Sample Use Guides

In Vivo Use Guide

The usual dose of LEVAQUIN tablets or oral solution is 250 mg, 500 mg, or 750 mg administered orally every 24 hours. The usual dose of LEVAQUIN Injection is 250 mg or 500 mg administered by slow infusion over 60 minutes every 24 hours or 750 mg administered by slow infusion over 90 minutes every 24 hours. Nosocomial Pneumonia: 750 mg during 7–14 days Community Acquired Pneumonia: 500 mg during 7–14 days Community Acquired Pneumonia§ 750 mg during 5 days Complicated Skin and Skin Structure Infections (SSSI) 750 mg during 7–14 days Uncomplicated SSSI 500 mg during 7–10 days Chronic Bacterial Prostatitis 500 mg during 28 days Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) 750 mg during 5 days Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) 250 mg during 10 days Uncomplicated Urinary Tract Infection 250 mg 3 during days Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) 500 mg during 7 days Acute Bacterial Sinusitis (ABS) 750 mg days or 500 mg during 10–14 days.

Route of Administration: Other

In Vitro Use Guide

Levofloxacin was compared to ofloxacin and ciprofloxacin against > 6000 recent clinical isolates of Gram-positive and Gram-negative bacteria from six different countries. This international multicenter study demonstrated a high level of antibacterial activity of levofloxacin against all the members of Enterobacteriaceae [minimum inhibitory concentration (MIC)50s, < or = 0.03 to 0.12 mg/L] except Providencia rettgeri (MIC50, 2 mg/L), and Providencia stuartii (MIC50, 1 mg/L). Levofloxacin was also active against non-enteric Gram-negative bacilli, including Acinetobacter species (MIC50s, < or = 0.03 to 1 mg/L), Pseudomonas species (MIC50s, 0.5 to 1 mg/L) and Xanthomonas maltophilia (MIC50, 0.5 mg/L). Overall, levofloxacin inhibited 50% and 90% of all the tested strains at the concentrations of 0.12 and 4 mg/L, respectively. The activity of levofloxacin was generally two-fold greater than ofloxacin and equal to or slightly less potent than ciprofloxacin.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:04:42 GMT 2025` Edited by `admin` on `Mon Mar 31 22:04:42 GMT 2025`
Record UNII	NHR291QA18
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LEVOFLOXACIN LACTATE

Common Name

English

(3S)-9-FLUORO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-2,3-DIHYDRO-7H-(1,4)OXAZINO(2,3,4-IJ)QUINOLINE-6-CARBOXYLIC ACID - 2-HYDROXYPROPANOIC ACID (1:1)

Preferred Name

English

7H-1,4-OXAZINO(2,3,4-IJ)QUINOLINE-6-CARBOXYLIC ACID, 9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-, (3S)-, COMPD. WITH 2-HYDROXYPROPANOIC ACID (1:1)

Systematic Name

English

PROPANOIC ACID, 2-HYDROXY-, COMPD. WITH (3S)-9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-7H-PYRIDO(1,2,3-DE)-1,4-BENZOXAZINE-6-CARBOXYLIC ACID (1:1)

Systematic Name

English

7H-PYRIDO(1,2,3-DE)-1,4-BENZOXAZINE-6-CARBOXYLIC ACID, 9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-, (3S)-, MONO(2-HYDROXYPROPANOATE)

Systematic Name

English

7H-PYRIDO(1,2,3-DE)-1,4-BENZOXAZINE-6-CARBOXYLIC ACID, 9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-, (3S)-, 2-HYDROXYPROPANOATE (1:1)

Systematic Name

English

Levofloxacin Lactate [WHO-DD]

Common Name

English

Code System Code Type Description

CAS

97853-07-1